Added to YB: 2025-11-20
Pitch date: 2025-11-19
NVO [neutral]
Novo Nordisk A/S
-22.86%
current return
Author Info
Compound & Fire shares at least one company deep dive every month. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 307.09
Price Target
228.00 (-4%)
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
value
Novo Nordisk ($NVO): A Quality Investing Deep Dive into the GLP-1 Leader's Long-Term Potential and Risks
NVO (short-term pass): Despite quality foundation structure, vertical integration & obesity TAM of 934M growing 7% annually (97% untapped), facing structural market share decline vs Lilly (80%→57% obesity, 56%→52% GLP-1). Compounding headwinds, potential US pricing pressure, patent cliff 2031-32. At 14x forward PE needs 13-15% FCF growth for 10% return. Quality company, insufficient margin of safety.
Read full article (69 min)